BJDRCT
Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis
A Phase 2 Randomized Trial.
ConclusionA single intravenous dose of recibokibart resulted in rapid improvement in pustular and overall skin disease severity in patients with acute GPP flares, with an acceptable safety profile.
Yang B, Li Y, … senior author Zhang FBritish Journal of Dermatology